A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report

被引：6
|
作者：
Wang, Jianzheng [1 ]
Li, Qingli [2 ]
Lv, Huifang [1 ]
Nie, Caiyun [1 ]
Chen, Beibei [1 ]
Xu, Weifeng [1 ]
Yang, Tiejun [3 ]
Zhang, Yinping [4 ]
Tu, Shuiping [2 ]
Chen, Xiaobing [1 ]
机构：
[1] Zhengzhou Univ, Dept Med Oncol, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China
[2] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Oncol, Shanghai, Peoples R China
[3] Zhengzhou Univ, Henan Canc Hosp, Dept Urol Surg, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[4] Zhengzhou Univ, Henan Canc Hosp, Dept Pathol, Affiliated Canc Hosp, Zhengzhou, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词：
PD-1; complete response; advanced; urothelial carcinoma; case report; CELL LUNG-CANCER; ADVERSE EVENTS; PNEUMONITIS; CHEMOTHERAPY; GEMCITABINE; CISPLATIN; TOXICITY; EFFICACY;
D O I：
10.3389/fonc.2021.671416
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The prognosis of patients with advanced urothelial carcinoma is dismal. Platinum-based chemotherapy is still the main first-line treatment for advanced urothelial carcinoma, while immunotherapy can be used as a first-line treatment option for people who cannot tolerate platinum. Immunotherapy is preferred in the second-line treatment of bladder urothelial carcinoma. PD-1 inhibitors (Pembrolizumab, nivolumab and atezolizumab) and PD-L1 inhibitors (Ddurvalumab and avelumab) have not been approved for the treatment of advanced urothelial cancer in China. We describe a patient with advanced urothelial carcinoma experienced disease progression after gemcitabine chemotherapy. Following a treatment of domestic PD-1 inhibitor (sintilimab), the patient achieved a durable complete response with mild toxicity. This case indicates that PD-1 inhibitor sintilimab might be a second-line treatment choice for advanced urothelial carcinoma.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Urothelial bladder carcinoma in childhood: a case report
    Zribi, Aref
    Ben Nasr, Sonia
    Msakni, Issam
    Karrit, Sarra
    Gargouri, Faten
    Fendri, Sana
    Balti, Mehdi
    Haddaoui, Abderrazek
    PAN AFRICAN MEDICAL JOURNAL, 2020, 36 : 1 - 5
  • [22] Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor
    Hwang, Inhwan
    Park, Inkeun
    Yoon, Shin-Kyo
    Lee, Jae Lyun
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (04) : 371 - 377
  • [23] Microcystic urothelial carcinoma of the bladder: A case report
    Kadouri, Youssef
    Zaoui, Youssef
    Derkaoui, Sabrine
    El Sayegh, Hachem
    Benslimane, Lounis
    Nouini, Yassine
    UROLOGY CASE REPORTS, 2020, 33
  • [24] Case Report: Potential Predictive Value of MMR/MSI Status and PD-1 Expression in Immunotherapy for Urothelial Carcinoma
    Ma, Yu-Ting
    Yang, Hong-Lan
    Yan, Li
    Hua, Fang
    Wang, Dong-Guan
    Xu, Guo-Ying
    Li, Yan
    Xue, Ying-Jie
    Qin, Ye-Jun
    Sha, Dan
    Ning, Hao
    Zhao, Miao-Qing
    Yao, Zhi-Gang
    PATHOLOGY & ONCOLOGY RESEARCH, 2022, 28
  • [25] Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report
    Zsófia Küronya
    Tímea Danyi
    Tímea Balatoni
    Gabriella Liszkay
    Erika Tóth
    Krisztina Biró
    Lajos Géczi
    Journal of Medical Case Reports, 16
  • [26] Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report
    Kuronya, Zsofia
    Danyi, Timea
    Balatoni, Timea
    Liszkay, Gabriella
    Toth, Erika
    Biro, Krisztina
    Geczi, Lajos
    JOURNAL OF MEDICAL CASE REPORTS, 2022, 16 (01)
  • [27] Remarkable response to gemcitabine rechallenge in advanced urothelial carcinoma: a case report
    Merler, Sara
    Pafumi, Sarah
    Zampiva, Ilaria
    Zacchi, Francesca
    Manduca, Stefano
    Fantinel, Emanuela
    Zivi, Andrea
    Milella, Michele
    ANTI-CANCER DRUGS, 2022, 33 (10) : 1171 - 1174
  • [28] Advanced Squamous Cell Carcinoma - Rapid Response to PD-1 Blockade
    Gellrich, F. F.
    Meier, F.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 16 - 16
  • [29] STATUS OF PD-1 AND PD-L1 EXPRESSION IN INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER WITH MISMATCH REPAIR PROTEIN DEFICIENCY
    Sungu, Nuran
    Kiran, Merve M.
    POLISH JOURNAL OF PATHOLOGY, 2023, 74 (03) : 161 - 170
  • [30] COMPLETE RESPONSE TO VINFLUNINE IN A PATIENT WITH METASTATIC UROTHELIAL CARCINOMA OF THE BLADDER
    Cerullo, Carmine
    Fonte, Carla
    Lunghi, Alice
    Neri, Bruno
    ANTICANCER RESEARCH, 2014, 34 (05) : 2639 - 2640
12345